New weekly shot aims to tackle fatty liver and obesity
NCT ID NCT05970640
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage trial tested an experimental drug called BI 3006337 in 64 adults who are overweight or obese and have fatty liver disease. Participants received weekly injections of either the drug or a placebo for about 4 months. The main goal was to check safety and tolerability, not yet to see if the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AMR Knoxville
Knoxville, Tennessee, 37920, United States
-
Accel Research Sites-Deland-67606
DeLand, Florida, 32720, United States
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Catalina Research Institute, LLC-Montclair-49051
Montclair, California, 91763, United States
-
Centricity Research-Columbus-68879
Columbus, Ohio, 43213, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Floridian Clinical Research-Miami Lakes-68368
Miami Lakes, Florida, 33016, United States
-
The Liver Institute at Methodist Dallas
Dallas, Texas, 75203, United States
-
Velocity Clinical Research-Chula Vista
Chula Vista, California, 91911, United States
-
Velocity Clinical Research-La Mesa-69117
La Mesa, California, 91942, United States
-
Velocity Clinical Research-West Jordan-69043
West Jordan, Utah, 84088, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 3006337 (an experimental drug given as a weekly injection)
What this could lead to
If it works, this could point toward a treatment for fatty liver disease in people with overweight or obesity.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to show benefit in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.